Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Oct 18, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict outcomes for patients with renal cell carcinoma (RCC) who have a tumor thrombus that invades the wall of the inferior vena cava (IVC), a large vein in the body. The goal is to create a reliable imaging model that can help doctors assess the extent of the invasion before surgery, which will be compared with actual tissue samples taken during surgery. Researchers want to understand how different levels of invasion affect long-term recovery and what this means for treatment options.

To participate in this trial, you must be an adult aged 18 or older, diagnosed with primary renal cell carcinoma that involves a tumor thrombus, and able to undergo surgery such as a radical nephrectomy (removal of the kidney) along with thrombectomy (removal of the thrombus). Participants will undergo various imaging tests before surgery and will be followed for three years after the procedure to monitor their health and recovery. This trial is currently recruiting participants and aims to improve how doctors approach treatment for patients with this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults ≥18 years of age;
• • Accepted abdominal ultrasonography, contrast-induced ultrasonography, enhanced CT and MRI before the surgery;
• • Diagnosis of primary renal cell carcinoma with tumor thrombus before and during the surgery;
• • Received radical nephrectomy and at least one kind of thrombectomy (including IVC incision only, IVC partial resection, IVC diagonal resection, and IVC segmental resection)
• • Can tolerate the surgery;
• • Eastern Cooperative Oncology Group Performance Status Scale (ECOG-PS) 0\~2;
• • No previous history of malignant tumor;
• • Willing to return for required follow-up visits
• Exclusion Criteria:
• • Failed to receive standard nephrectomy for any reason;
• • Attached other addition operations in the surgery;
• • Received neoadjuvant treatment before the surgery;
• • Experience any other conditions that may affect the curative effect (e.g. active tuberculosis, autoimmune disease, or oral glucocorticoids treatment);
• • Experience serious consequences or death due to anesthesia accident during operation;